These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25483147)

  • 1. Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.
    Pilleri M; Antonini A
    Expert Opin Drug Saf; 2015 Feb; 14(2):281-94. PubMed ID: 25483147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.
    Stathis P; Konitsiotis S; Antonini A
    Expert Rev Neurother; 2015 Feb; 15(2):207-13. PubMed ID: 25578445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of levodopa-induced dyskinesias.
    Rascol O
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S179-88. PubMed ID: 10762146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
    Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of levodopa-induced dyskinesia].
    Rascol O; Ferreira JJ; Payoux P; Brefel-Courbon Ch; Montastruc JL
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S117-24. PubMed ID: 12690671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Thanvi B; Lo N; Robinson T
    Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.
    Rascol O
    J Neurol; 2000 Apr; 247 Suppl 2():II51-7. PubMed ID: 10991666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease.
    Gottwald MD
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):162S-8S. PubMed ID: 10555944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing levodopa-induced dyskinesias.
    Olanow CW; Obeso JA
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatments for levodopa-induced motor complications.
    Rascol O; Perez-Lloret S; Ferreira JJ
    Mov Disord; 2015 Sep; 30(11):1451-60. PubMed ID: 26293004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
    Schelosky L; Poewe W
    Acta Neurol Scand Suppl; 1993; 146():46-9. PubMed ID: 8101415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment and future prospects of dopa-induced dyskinesias.
    Mazzucchi S; Frosini D; Bonuccelli U; Ceravolo R
    Drugs Today (Barc); 2015 May; 51(5):315-29. PubMed ID: 26097904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients.
    Dragašević-Mišković N; Petrović I; Stanković I; Kostić VS
    Expert Opin Pharmacother; 2019 Feb; 20(2):219-230. PubMed ID: 30411647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.